Webinar: Strategies and Considerations for IPR Petitioners Working with Other Interested Parties

Recent decisions by both the U.S. Patent Office Patent Trial and Appeal Board and Federal Courts are significantly affecting the landscape for Inter Partes Review and other post-grant proceeding petitions. These include Court decisions affecting the effective level of the PTAB’s control over Institution Decisions. These recent trends make strategic planning critical in the dynamic between customers and suppliers/service providers faced with infringement suits and threats. Early missteps in the IPR petition process can hinder or even doom success at the later stages.

Join Foley & Lardner LLP for a webinar discussing how recent PTAB and Federal Court decisions may affect the strategies used for Inter Partes Review and other post-grant proceeding petitions when other interested parties are involved. Such considerations arise, for example, in the context of customer/client-supplier/service provider relationships, and when another party has already filed an IPR petition on the same patent.

Real Party in Interest (RPI) and “privy” issues, including factors relating to naming a supplier or customer in an IPR petition
Timing issues and the reviewability of Institution Decisions
How Click-to-Call may affect reviewability of PTAB Institution Decisions
Consideration of Joinder motions for instituted IPRs
Chances of success when presenting the same or substantially the same arguments, parallel petitions, or a follow-on petition
PTAB discretion in instituting IPR post-SAS
PTAB trends in deciding such petitions
Limits to appealing PTAB decisions to the Federal Circuit
How standing for appeals may affect strategy for petition filing

A man in a business suit stands indoors, smiling at the camera, with a blurred corporate law office hallway in the background.

[email protected]

Washington, D.C. 202.945.6162

Man in a dark pinstripe suit, white shirt, and striped tie, standing and smiling in front of a blurred indoor background—an embodiment of Chicago lawyers experienced in litigation support.

[email protected]

Chicago 312.832.4378

Related Insights

View All Posts

December 4, 2025 Manufacturing Industry Advisor

Foley Automotive Update

Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…

December 4, 2025 Foley Viewpoints

Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift

Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.

December 4, 2025 Foley Viewpoints

FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation

FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…

Webinar: Strategies and Considerations for IPR Petitioners Working with Other Interested Parties

People

Pavan K. Agarwal

Michael R. Houston

Related Insights

Foley Automotive Update

Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift

FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation